

To: (10)(2e) <(10)(2e)@rivm.nl>
Cc: (10)(2e) <(10)(2e)@ecdc.europa.eu>; (10)(2e) <(10)(2e)@ecdc.europa.eu>
From: (10)(2e)
Sent: Thur 10/1/2020 10:55:09 AM
Subject: RE: Shenzhen BioEasy diagnostic accuracy
Received: Thur 10/1/2020 10:55:15 AM

Dear (10)(2e)

The assay reported by Portugal was (10)(1c) (2019-nCoV) Ag Test (Fluorescence Immunochromatographic Assay)", so I assume indeed it was the fluorescence assay.

Kind regards,

(10)(2e)

From: (10)(2e) <(10)(2e)@rivm.nl>
Sent: 27 September 2020 12:58
To: (10)(2e) <(10)(2e)@ecdc.europa.eu>
Cc: (10)(2e) <(10)(2e)@ecdc.europa.eu>; (10)(2e) <(10)(2e)@ecdc.europa.eu>
Subject: RE: (10)(2e) diagnostic accuracy

Many thanks (10)(2e)

Do you know which version of the BioEasy assay (10)(2e) used? The visual readout or the fluorescent assay? The fluorescent assay as far as I can see has very good performance whereas the visual readout assay has been discontinued by BioEasy because of bad performance.

A similar difference in sensitivity has been shown for the Q Biosensor and F Biosensor assays.

Best regards,

(10)(2e)

From: (10)(2e) <(10)(2e)@ecdc.europa.eu>
Sent: donderdag 24 september 2020 09:13
To: (10)(2e) <(10)(2e)@rivm.nl>
Cc: (10)(2e) <(10)(2e)@ecdc.europa.eu>; (10)(2e) <(10)(2e)@ecdc.europa.eu>
Subject: Shenzhen BioEasy diagnostic accuracy

Dear (10)(2e)

I wanted to get back to you on your question yesterday during the network meeting regarding the BioEasy antigen test. We have the following data on that:


1. Data contributed by the National Influenza Reference Laboratory and other Respiratory Viruses at INSA in (headed by (10)(2e)): sensitivity (10)(1c)
2. (10)(2e) (attached): sensitivity (10)(1c)
3. (10)(2e) (attached): sensitivity (10)(1c) However, the paper mentions "Seventeen of the positive specimens had been used in a previous evaluation of the Bioeasy RDT by our group", which is the (10)(2e) study above. Since there is no way of knowing which samples were reused, we did not include this study to avoid redundancy and possible bias. It is also a bit strange that between both publications first and last author are switched. The results for the other antigen tests from this study were kept.

Since there is limited data available and a very large difference between (1) and (2), I would advise to be very careful with interpreting these results (see also the forest plot below from the supplementary material). It may be good to contact (10)(2e) <(10)(2e)@insa.min-saude.pt> to get some more information, if you are interested.

Hope this helps. For further discussion, please check with (10)(2e) (cc) since I am sort of on holiday.

Kind regards,

(10)(2e)



(10)(2e)
PhD
Expert Public Health Bioinformatics
Surveillance, PHF
Phone +46 (0)8 58 60 1258
(10)(2e) @ecdc.europa.eu

**European Centre for
Disease Prevention and Control (ECDC)**

Gustav III:s boulevard 40, 169 73 Solna, Sweden
Phone +46 (0)8 58 60 10 00 / Fax +46 (0)8 58 60 10 01
www.ecdc.europa.eu

Follow ECDC on:



Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.
www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.
www.rivm.nl/en Committed to health and sustainability